Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Asadi, Shahrzad ^a,b   Theoharides, Theoharis C ^a,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; LUTEOLIN; MESSENGER RNA; MITOCHONDRIAL DNA; VASCULOTROPIN;

ALLERGIC INFLAMMATION; ARTICLE; AUTISM; CELL STIMULATION; CELL STRESS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MAST CELL; MITOCHONDRION; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS;

EID: 84860517661     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-85     Document Type: Article

References (47)

1. Ashwood P, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006, 80:1-15. 10.1189/jlb.1205707, 16698940.
2. Atladottir HO, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, Parner ET. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009, 124:687-694. 10.1542/peds.2008-2445, 19581261.
3. Theoharides TC, Kempuraj D, Redwood L. Autism: an emerging 'neuroimmune disorder' in search of therapy. Exp Opinion on Pharmacotherapy 2009, 10:2127-2143.
4. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007, 217:65-78. 10.1111/j.1600-065X.2007.00519.x, 17498052.
5. Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med 2006, 160:825-830. 10.1001/archpedi.160.8.825, 16894082.
6. Jyonouchi H, Geng L, Cushing-Ruby A, Quraishi H. Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. J Neuroinflammation 2008, 5:52. 10.1186/1742-2094-5-52, 2625336, 19025588.
7. Bakkaloglu B, Anlar B, Anlar FY, Oktem F, Pehlivanturk B, Unal F, Ozbesler C, Gokler B. Atopic features in early childhood autism. Eur J Paediatr Neurol 2008, 12:476-479. 10.1016/j.ejpn.2007.12.008, 18272414.
8. Magalhaes ES, Pinto-Mariz F, Bastos-Pinto S, Pontes AT, Prado EA, Deazevedo LC. Immune allergic response in Asperger syndrome. J Neuroimmunol 2009, 216:108-112. 10.1016/j.jneuroim.2009.09.015, 19840888.
9. Angelidou A, Alysandratos KD, Asadi S, Zhang B, Francis K, Vasiadi M, Kalogeromitros D, Theoharides TC. Brief report: " allergic symptoms" in children with autism spectrum disorders. more than meets the eye?. J Autism Dev Disord 2011, 41:1579-1585. 10.1007/s10803-010-1171-z, 21210299.
10. White SW, Oswald D, Ollendick T, Scahill L. Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev 2009, 29:216-229. 10.1016/j.cpr.2009.01.003, 2692135, 19223098.
11. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL, Theoharides TC. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005, 174:7665-7675.
12. Angelidou A, Francis K, Vasiadi M, Alysandratos K-D, Zhang B, Theoharides A, Lykouras L, Kalogeromitros D, Theoharides TC. Neurotensin is increased in serum of young children with autistic disorder. J Neuroinflammation 2010, 7:48. 10.1186/1742-2094-7-48, 2936302, 20731814.
13. Fassio A, Evans G, Grisshammer R, Bolam JP, Mimmack M, Emson PC. Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody. Neuropharmacology 2000, 39:1430-1442. 10.1016/S0028-3908(00)00060-5, 10818259.
14. Boucher J. Research Review: Structural language in autistic spectrum disorder - characteristics and causes. J Child Psychol Psychiatry 2012, 53:219-233. 10.1111/j.1469-7610.2011.02508.x, 22188468.
15. Zhang B, Angelidou A, Alysandratos KD, Vasiadi M, Francis K, Asadi S, Theoharides A, Sideri K, Lykouras L, Kalogeromitros D, Theoharides TC. Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. J Neuroinflammation 2010, 7:80. 10.1186/1742-2094-7-80, 3001695, 21083929.
16. Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W, House M, Wolferg A, Theoharides TC. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol 2008, 155:1076-1084. 2597265, 18806808.
17. Asadi S, Zhang B, Weng Z, Angelidou A, Kempuraj D, Alysandratos KD, Theoharides TC. Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. Int J Immunopathol Pharmacol 2010, 23:1015-1020.
18. Kempuraj D, Saito H, Kaneko A, Fukagawa K, Nakayama M, Toru H, Tomikawa M, Tachimoto H, Ebisawa M, Akasawa A, Miyagi T, Kimura H, Nakajima T, Tsuji K, Nakahata T. Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood 1999, 93:3338-3346.
19. McCary C, Tancowny BP, Catalli A, Grammer LC, Harris KE, Schleimer RP, Kulka M. Substance P downregulates expression of the high affinity IgE receptor (FcepsilonRI) by human mast cells. J Neuroimmunol 2010, 220:17-24. 10.1016/j.jneuroim.2009.12.006, 20117843.
20. Kirshenbaum AS, Swindle E, Kulka M, Wu Y, Metcalfe DD. Effect of lipopolysaccharide (LPS) and peptidoglycan (PGN) on human mast cell numbers, cytokine production, and protease composition. BMC Immunol 2008, 9:45. 10.1186/1471-2172-9-45, 2527549, 18687131.
21. Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis K, Toniato E, Kalogeromitros D. Mast cell activation and autism. Biochim Biophys Acta 2012, 1822(1):34-41. 10.1016/j.bbadis.2010.12.017, 21193035.
22. Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Theoharides TC. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 2006, 103:7759-7764. 10.1073/pnas.0602210103, 1472518, 16682628.
23. Gillott A, Standen PJ. Levels of anxiety and sources of stress in adults with autism. J Intellect Disabil 2007, 11:359-370. 10.1177/1744629507083585, 18029412.
24. Ercan F, San T, Cavdar S. The effects of cold-restraint stress on urinary bladder wall compared with interstitial cystitis morphology. Urol Res 1999, 27:454-461. 10.1007/s002400050135, 10651134.
25. Esposito P, Chandler N, Kandere-Grzybowska K, Basu S, Jacobson S, Connolly R, Tutor D, Theoharides TC. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002, 303:1061-1066. 10.1124/jpet.102.038497, 12438528.
26. Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 2007, 12:1615-1628. 10.2741/2174, 17127408.
27. Esposito P, Gheorghe D, Kandere K, Pang X, Conally R, Jacobson S, Theoharides TC. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001, 888:117-127. 10.1016/S0006-8993(00)03026-2, 11146058.
28. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, Chrousos G. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. Endocrinology 1998, 139:403-413. 10.1210/en.139.1.403, 9421440.
29. Wright GL, Maroulakou IG, Eldridge J, Liby TL, Sridharan V, Tsichlis PN, Muise-Helmericks RC. VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase. FASEB J 2008, 22:3264-3275. 10.1096/fj.08-106468, 2518259, 18524868.
30. Palmieri L, Persico AM. Mitochondrial dysfunction in autism spectrum disorders: Cause or effect?. Biochim Biophys Acta 2010, 1797:1130-1137. 10.1016/j.bbabio.2010.04.018, 20441769.
31. Weissman JR, Kelley RI, Bauman ML, Cohen BH, Murray KF, Mitchell RL, Kern RL, Natowicz MR. Mitochondrial disease in autism spectrum disorder patients: A cohort analysis. PLoS One 2008, 3:e3815. 10.1371/journal.pone.0003815, 2584230, 19043581.
32. Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res 2011, 69:41R-47R. 10.1203/PDR.0b013e318212f16b, 3179978, 21289536.
33. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006, 125:1241-1252. 10.1016/j.cell.2006.06.010, 16814712.
34. Twig G, Hyde B, Shirihai OS. Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim Biophys Acta 2008, 1777:1092-1097. 10.1016/j.bbabio.2008.05.001, 18519024.
35. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107. 10.1038/nature08780, 2843437, 20203610.
36. Goines P, Van de Water J. The immune system's role in the biology of autism. Curr Opin Neurol 2010, 23:111-117. 10.1097/WCO.0b013e3283373514, 2898160, 20160651.
37. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000, 52:673-751.
38. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, Cetrulo CL, Theoharides TC. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005, 145:934-944. 10.1038/sj.bjp.0706246, 1576204, 15912140.
39. Franco JL, Posser T, Missau F, Pizzolatti MG, Dos Santos AR, Souza DO, Aschner M, Rocha JB, Dafre AL, Farina M. Structure-activity relationship of flavonoids derived from medicinal plants in preventing methylmercury-induced mitochondrial dysfunction. Environ Toxicol Pharmacol 2010, 30:272-278. 10.1016/j.etap.2010.07.003, 2992974, 21127717.
40. Theoharides TC. Luteolin as a therapeutic option for multiple sclerosis. J Neuroinflammation 2009, 6:29. 10.1186/1742-2094-6-29, 2768692, 19825165.
41. Theoharides TC, Asadi S, Panagiotou JP. Effect of a luteolin formulation (NeuroProtek) on autism spectrum disorders-A case series. Int J Immunopathol and Pharmacol 2012, In press.
42. Theoharides TC, Zhang B. Neuro-inflammation, blood-brain barrier. Seizures and Autism J Neuroinflammation. 2011, 8:168.
43. Theoharides TC, Doyle R, Francis K, Conti P, Kalogeromitros D. Novel therapeutic targets for autism. Trends Pharmacol Sci 2008, 29:375-382. 10.1016/j.tips.2008.06.002, 18606459.
44. Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis K, Toniato E, Kalogeromitros D. Mast cell activation and autism. Biochim Biophys Acta 1822, 2012:34-41.
45. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. Neurotoxicology 2008, 29:190-201. 10.1016/j.neuro.2007.09.010, 18031821.
46. Herbert MR. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol 2010, 23:103-110. 10.1097/WCO.0b013e328336a01f, 20087183.
47. Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011, 128:147-152. 10.1016/j.jaci.2011.04.037, 21621255.